Español

CONTACT


    DR. FERNANDO ALARID-ESCUDERO

    Education:

    • 2017 – Ph.D., Health Services Research, Policy & Administration, University of Minnesota.
    • 2009 – Master in Economics, CIDE.
    • 2006 – Biomedical Engineering, Metropolitan Autonomous University, Iztapalapa

    Academic appointments:

    • Professor-researcher at the Division of Public Administration (DAP) at the Center for Research and Teaching in Economics (CIDE) Central Region in Aguascalientes, Mexico.
    • Member of the Cancer Surveillance and Intervention Modeling Network (CISNET).
    • Researcher affiliated with CISIDAT.
    • Level 1 in the National System of Researchers (SNI)
    • Founding partner of the Decision Analysis in R for Technologies in Health working group (DARTH; http://darthworkgroup.com/)

    Research interests:

    • Application and development of epidemiological, computational, economic, statistical, and decision analysis models for health problems and public health policies.
    • Development of novel methods to quantify the value of future research.

    Featured projects:

    • Modeling the COVID-19 epidemic in Mexico and other parts of the world with the SC-COSMO model (www.sc-cosmo.org).
    • Impact evaluation of different detection and treatment policies for colorectal, cervical, and gastric cancers, and infectious disease agents as precursors of cancers such as human papillomavirus (HPV) and Helicobacter pylori (H. pylori) on health and quality life of the population.
    • Cost-effectiveness analysis of different HIV / AIDS prevention interventions in Central America.
    • Methodological work: co-developed a new efficient method to perform information value analysis (VOI) using a Gaussian approximation approach. He defined the problem of non-identifiability in the calibration of simulation models and its implications for decision-making in health. He implemented new Bayesian calibration methodologies to quantify and propagate the uncertainty of a colorectal cancer natural history model’s parameters to assess its impact on health policy analysis. He has also developed open-source software to quantify future research value and estimate the price based on the value of healthcare technologies. He developed an open-source framework for building cost-effectiveness analyzes based on decision models. He quantified the extrapolation bias by using clinical trial parameters used to extrapolate the effectiveness of health technologies beyond the evaluation period and proposed a new method to eliminate this bias.

     

    SELECTED PUBLICATIONS

    • Alarid-Escudero F∗, Schrag D, Kuntz KM. CDX2 biomarker testing and adjuvant therapy for stage II colon cancer: An exploratory cost-effectiveness analysis. Value in Health, 2021 (Online First).
    • Alarid-Escudero F∗, Gracia V, Luviano A, Roa J, Peralta Y, Reitsma MB, Claypool AL, Salomon JA, Studdert DM, Andrews, JR, Goldhaber-Fiebert JD, SC-COSMO Modeling Consortium. De- pendence of Covid-19 policies on end-of-year holiday contacts in Mexico City Metropolitan Area: A Modeling Study. Medical Decision Making Policy & Practice, 2021 (Online First).
    • Lopez Mendez M‡, Ospina Escobar AM, Iskandar R, Alarid-Escudero F∗. Age-Specific Rates of Onset of Cannabis Use in Mexico. Addictive Behaviors, 2021;122(107038):1-8.
    • Ryckman T, Chin ET, Prince L, Leidner D, Long E, Studdert DM, Salomon JA, Alarid-Escudero F, Andrews, JR, Goldhaber-Fiebert JD. Outbreaks of COVID-19 Variants in U.S. Prisons: A Math- ematical Modeling Analysis of Vaccination and Re-Opening Policies. The Lancet Public Health, 2021 (Online First).
    • Chin ET, Leidner D, Ryckman T, Liu Y, Prince L, Alarid-Escudero F, Andrews JR, Salomon JA, Goldhaber-Fiebert JD, Studdert DM. Covid-19 Vaccine Acceptance among Residents of California State Prisons. New England Journal of Medicine, 2021 (Online First).
    • Caro-Vega Y, Alarid-Escudero F, Enns EA, Sosa-Rubí SG, Chivardi C, Piñeirúa-Menendez A, García-Morales C, Reyes-Terán G, Sierra-Madero JG, Ávila-Ríos S. Retention in Care, Mortality, Loss-to-Follow-Up, and Viral Suppression among Antiretroviral Treatment-Naïve and Experienced Persons Participating in a Nationally Representative HIV Pre-Treatment Drug Resistance Survey in Mexico Pathogens, 2021; 10(12):1569.
    • Chin ET, Ryckman T, Prince L, Leidner D, Alarid-Escudero F, Andrews, JR, Salomon JA, Stud- dert DM, Goldhaber-Fiebert JD. COVID-19 in the California State Prison System: an Observational Study of Decarceration, Ongoing Risks, and Risk Factors. Journal of General Internal Medicine, 2021 (Online First).
    • Kuntz KM, Alarid-Escudero F, Swiontkowski M, Skaar DD. Prioritizing research informing antibi- otic prophylaxis guidelines for knee arthroplasty patients. JDR Clinical & Translational Research, 2021 (Online First).
    • Jalal H, Trikalinos T, Alarid-Escudero F. BayCANN: Streamlining Bayesian Calibration with Artificial Neural Network Metamodeling. Frontiers in Physiology (Computational Physiology and Medicine), 2021;12(66231):1-13.
    • Lansdorp-Vogelaar I, Meester RGS, Laszkowskab M, Alarid-Escudero F, Ward Z, Yeh J. Cost- effectiveness of prevention and early detection of gastric cancer in western countries. Best Practice & Research Clinical Gastroenterology, 2021;50–51(101735):1-8.
    • Peterse, EFP, Meester, RGS, Jonge, LDe, Omidvari, A-H, Alarid-Escudero F, Knudsen, AB, Za- uber, AG, Lansdorp-Vogelaar, I. Comparing the cost-effectiveness of innovative colorectal cancer screening tests. Journal of the National Cancer Institute, 2021;113(2):154-161.
    • Fung H, Martinez L, Alarid-Escudero F, Salomon JA, Studdert DM, Andrews JA, Goldhaber- Fiebert JD, SC-COSMO Modeling Group. The household secondary attack rate of SARS-CoV-2: A rapid review. Clinical Infectious Diseases, 2020 (Online First).
    • Alarid-Escudero F∗, Kuntz KM. Potential bias associated with modeling the effectiveness of health- care interventions in reducing mortality using an overall hazard ratio. PharmacoEconomics, 2020; 38(3):285-296.
    • Kunst NR, Alarid-Escudero F, Aas E, Coupé VMH, Schrag D, Kuntz KM. Estimating population- based recurrence rates of colorectal cancer over time in the United States. Cancer Epidemiology, Biomarkers & Prevention, 2020;29(12):2710-2718.
    • Huang RJ, Koh H, Hwang JH, Abnet CC, Alarid-Escudero F, Amieva MR, Bruce MG, Camargo MC, Chan AT, Choi IJ, Corvalan A, Davis JL, Deapen D, Epplein M, Greenwald DA, Hamashima C, Hur C, Inadomi JM, Ji HP, Jung HY, Lee E, Lin B, Palaniappan LP, Parsonnet J, Peek RM, Pi-azuelo MB, Rabkin CS, Shah SC, Smith A, So S, Stoffel EM, Umar A, Wilson KT, Woo Y, Yeoh K. A Summary of the 2020 Gastric Cancer Summit at Stanford University. Gastroenterology, 2020;159(4):1221- 1226.
    • Sosa-Rubí, S., Contreras-Loya, D., Pedraza-Arizmendi, D., Chivardi-Moreno, C., Alarid-Escudero, F., López-Ridaura, R., Serván-Mori, E., Molina-Cuevas, V., Casales, G., Espinos-López, C., González- Roldán, J. F., Silva-Tinoco, R., Seiglie, J., & Gómez-Dantés, O. (2020). Cost-effectiveness analysis of a multidisciplinary health-care model for patients with type-2 diabetes implemented in the pub-lic sector in Mexico: A quasi-experimental, retrospective evaluation. Diabetes Research and Clinical Practice, 2020;167(108336):1-8.
    • Krijkamp E†, Alarid-Escudero F†∗, Enns EA, Pechlivanoglou P, Hunink MGM, Yang A, Jalal H. A Multidimensional Array Representation of State-transition Model Dynamics Medical Decision Making, 2020;40(2):242-248.
    • Holt HK, Kulasingam S, Sanstead EC, Alarid-Escudero F, Smith-McCune K, Gregorich SE, Sil- verberg M, Huchko MJ, Kuppermann M, Sawaya G Discussing Cervical Cancer Screening Options: Outcomes to Guide Conversations Between Patients and Providers. Medical Decision Making Policy & Practice, 2020;5(2):1-7.
    • Kunst NR, Wilson E, Glynn D, Alarid-Escudero F, Baio G, Brennan A, Fairley M, Goldhaber- Fiebert JD, Jackson C, Jalal H, Menzies N, Strong M, Thom H, Heath A, on behalf of the Collaborative Network for Value of Information (ConVOI). Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. Value in Health, 2020;23(6):734-742.
    • Heath A, Kunst NR, Jackson C, Strong M, Alarid-Escudero F, Goldhaber-Fiebert JD, Baio G, Menzies N, Jalal H. Calculating the Expected Value of Sample Information in Practice: Considera- tions from Three Case Studies. Medical Decision Making, 2020;40(3):314-326.
    • Burger EA, de Kok IMCM, Groene E, Killen J, Canfell C, Kulasingam S, Kuntz KM, Matthijsse S, Regan C, Simms K, Sy S, Alarid-Escudero F, Vaidyanathan V, van Ballegooijen M, Kim JJ. Es- timating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Com- parative Analysis. JNCI Journal of the National Cancer Institute, 2020;112(9):955-963.
    • Attanasio LB, Alarid-Escudero F, Kozhimannil KB. Midwife-led care and obstetrician-led care for low-risk pregnancies: A cost comparison Birth, 2020;47(1):57-66.
    • Alarid-Escudero F∗, Krijkamp E, Pechlivanoglou P, Jalal H, Kao SY, Yang A, Enns EA. A need for change! A coding framework for improving transparency in decision modeling. PharmacoEco- nomics, 2019;37(11):1329-1339.
    • Alarid-Escudero F∗, Enns EA, Kuntz KM, Michaud TL, Jalal H. “Time Traveling Is Just Too Dangerous” But Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. Value in Health, 2019;22(5):611-618.
    • Sawaya G, Sanstead E, Alarid-Escudero F, Smith-McCune K, Gregorich SE, Silverberg M, Leyden W, Huchko MJ, Kuppermann M, Kulasingam S Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis. JAMA In- ternal Medicine, 2019;179(7):867-878.
    • Kunst N, Alarid-Escudero F, Paltiel D, Wang SY. A value of information analysis of research on the 21-gene assay for breast cancer management. Value in Health, 2019;22(10):1102-1110.
    • Jutkowitz E, Alarid-Escudero F∗, Kuntz KM, Jalal H. The Curve of Optimal Sample Size (COSS): a Graphical Representation of the Optimal Sample Size from a Value of Information Analysis. Phar- macoEconomics, 2019;37(7):871-877.
    • Sathianathen NJ, Alarid-Escudero F, Kuntz KM, Lawrentschuk NL, Bolton DM, Murphy DG, Kim SP, Konety BR. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone- sensitive Prostate Cancer. European Urology Oncology, 2019;2(6):649-755.
    • Sathianathen NJ, Konety BR, Alarid-Escudero F, Lawrentschuk NL, Bolton DM, Murphy DG, Weight CJ, Kuntz KM. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. European Urology, 2019;75(6):910-917.
    • Alarid-Escudero F∗, MacLehose RF, Peralta Y, Kuntz KM, Enns EA. Non-identifiability in model calibration and implications to medical decision making. Medical Decision Making, 2018;38(7):810- 21.
    • Easterly CA‡, Alarid-Escudero F∗, Enns EA, Kulasingam S. Revisiting Assumptions about Age- Based Mixing Representations in Mathematical Models of Sexually Transmitted Infections. Vaccine, 2018;36(37):5572-5579.
    • Alarid-Escudero F∗, Enns EA, MacLehose R, Parsonnet J, Torres J, Kuntz KM. Force of infec- tion of H. pylori in Mexico: Evidence from a national survey using a hierarchical Bayesian model. Epidemiology and Infection, 2018;146(8):961-9.
    • Sathianathen NJ, Kuntz KM, Alarid-Escudero F, Lawrentschuk NL, Bolton DM, Murphy DG, Weight CJ, Konety BR. Incorporating biomarkers into the primary prostate biopsy setting: a cost- effectiveness analysis. The Journal of Urology, 2018;200(6):1215-1220.
    • Krijkamp EM, Alarid-Escudero F, Enns EA, Jalal H, Hunink MGM, Pechlivanoglou P. Microsim- ulation modeling for health decision sciences using R: A tutorial. Medical Decision Making, 2018;38(3):400- 422.
    • Jalal H, Alarid-Escudero F. A Gaussian Approximation Approach for Value of Information Analy- sis. Medical Decision Making, 2018;38(2):174-188.
    • Jutkowitz E, Alarid-Escudero F, Choi HK, Kuntz KM, Jalal H. Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. Pharma- coEconomics, 2017;35(10):1073-1085.
    • Alarid-Escudero F∗, Blaes A, Kuntz KM. Trade-offs between efficacy and cardiac toxicity of ad- juvant chemotherapy in early-stage breast cancer patients: Do competing risks matter? The Breast Journal, 2017;23(4):401-9.
    • Jalal H, Pechlivanoglou P, Krijkamp E, Alarid-Escudero F, Enns EA, Hunink, MGM. An Overview of R in Health Decision Sciences. Medical Decision Making, 2017;37(7):735-746.
    • Drake C, Higuera L, Alarid-Escudero F, Feldman R. A kinked health insurance market: Employer- sponsored insurance under the Cadillac tax. American Journal of Health Economics, 2017;3(4):455- 76.
    • Kozhimannil KB, Hardeman RR, Alarid-Escudero F, Vogelsang C, Blauer-Peterson C, Howell EA. Modeling the cost-effectiveness of doula care for reducing preterm birth and cesarean delivery. Birth. 2016;43(1):20-27.
    • Alarid-Escudero F, Sosa-Rubí SG, Fernández B, Galárraga O. Cost-benefit analysis: HIV/AIDS prevention in migrants in Central America. Salud Pública de México. 2013;55(S1):S23-30.
    • Alarid-Escudero F∗, Solís-Escalante T., Melgar E., Valdés-Cristerna R., Yánez-Suárez O. Registro de seńales de EEG para aplicaciones de interfaz cerebro computadora (ICC) basado en Potenciales Evocados Visuales de Estado Estacionario (PEVEE). CLAIB 2007 IFMBE Proceedings, 2007;18:87– 90.

    Book Chapters

    • Alarid-Escudero F, Gulati R, Rutter CM. Validation of Microsimulation Models Used for Popula- tion Health Policy In: Complex Systems and Population Health. Edited by Yorghos Apostolopou- los, Kristen Hassmiller Lich, and Michael Kenneth Lemke, Oxford University Press (2020).